Guideline History and Scope
The Abnormal Uterine Bleeding Working Group (AUBWG) was originally created in 2004 to develop evidence-based, consensus guidelines for the management of abnormal uterine bleeding for women in Kaiser Permanente's Southern California (KPSC) Region (see Sidebar: Members of the Abnormal Uterine Bleeding Working Group). The Southern California Permanente Medical Group (SCPMG) is the only Medical Group contracted to provide care for the more than three million members of the Kaiser Foundation Health Plan in the Southern California Region. The AUBWG determined that the scope of these guidelines included the investigation and initial management of women with postmenopausal bleeding thought or known to emanate from the vagina. a1 The first version of these guidelines, based on evidence published to December 2004, was completed in 2005 and published in an abbreviated format on the Guideline Clearinghouse Web site of the Agency for Healthcare Research and Quality, with the full text made available on request. This version of the guidelines includes the result of a major systematic review of the evidence published since January 2005.
Postmenopausal uterine bleeding, either spontaneous or that related to ovarian hormone replacement therapy (HRT) or selective estrogen receptor modulator (SERM) use (eg, tamoxifen adjuvant therapy for breast carcinoma) collectively results in a substantial number of patient encounters. These encounters directly involve physicians and other clinicians in the Departments of Family Medicine, Internal Medicine, Obstetrics and Gynecology, and Oncology and include physicians, nurse practitioners, and other midlevel clinicians. The clinical problem also indirectly affects medical clinicians and resources in the Departments of Radiology and Pathology, particularly because of the use of endometrial sampling and imaging of the uterus. Consequently, recommendations have been developed considering this diverse spectrum of practitioners and departments.
Methods
The Chair of the AUBWG was selected by the Regional Chief of Obstetrics and Gynecology for SCPMG. The remaining members of the AUBWG were selected by the chairs of each of the 12 KPSC Medical Centers on the basis of their interest in abnormal uterine bleeding and ability to contribute to guideline development.
After an introductory discussion on the general and SCPMG-specific issues involved in the investigation of postmeno-
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Investigation of Women with Postmenopausal Uterine Bleeding: Clinical Practice Recommendations pausal bleeding, the committee met as a whole to review methods of guideline development, agree on terms for evidence classification, define basic terms (Table 1) and to come to consensus on the scope of the guidelines to be developed. (See prior section, Guideline History and Scope; Tables 2 and 3 ; the Sidebars: Problem Formation and Suggested Contents for Report of Endometrial Echo Complex Evaluation.) The Working Group Chair prepared a template to aid the guideline development process. For the revision process, the existing document underwent a draft revision following a systematic review of the literature.
For the original review, a subgroup of three individuals was charged with leading the investigation and developing draft documents for meetings of the whole group. Drafts were distributed electronically to the whole group, and monthly face-to-face meetings were used to obtain feedback from each of the members of the committee. For this major revision, all members of the AUBWG were involved in the review and revision process with two face-to-face meetings and teleconferences as appropriate.
Literature searches were performed in MEDLINE and The Cochrane Database of Systematic Reviews between January 1, 2005 and November 19, 2012, using the following search terms: postmenopausal uterine bleeding, transvaginal ultrasound, sonohysterography, saline infusion sonography, hysteroscopy, endometrial biopsy, tamoxifen, and hormone replacement therapy (see Sidebar: Evidence Tables  [available from: www.thepermanentejournal.org/files/Winter2014/EvidenceSearch. pdf). Also searched were the Web sites of the American College of Obstetricians and Gynecologists (www.acog.org/Resources_ And_Publications), the Society of Obstetricians and Gynecologists of Canada (http:// sogc.org/clinical-practice-guidelines/), the New Zealand Guidelines Group (www. health.govt.nz/about-ministry/ministryhealth-websites/new-zealand-guidelinesgroup), the National Institute for Health Spontaneous uterine bleeding that occurs more than one year after the date of the last menstrual period Breakthrough bleeding Unscheduled uterine bleeding encountered in any postmenopausal woman using hormone replacement therapy Satisfactory endometrial biopsy
Comprises perceptible passage of the sampling device through the cervical canal into the endometrial cavity and appropriate functioning of the aspiration mechanism. Adequacy of the specimen for histologic interpretation is determined by the pathologist. Intervention improves important health outcomes, based on good evidence, and the GDT concludes that benefits substantially outweigh harms and costs B GDT recommends that clinicians routinely provide the intervention to eligible patients
Intervention improves important health outcomes, based on 1) good evidence that benefits outweigh harms and costs or 2) fair evidence that benefits substantially outweigh harms and costs C GDT makes no recommendation for or against routine provision of the intervention. At the discretion of the GDT, the recommendation may use the language "option," but must list all the equivalent options.
Evidence is sufficient to determine the benefits, harms, and costs of an intervention, and there is at least fair evidence that the intervention improves important health outcomes. However, the GDT concludes that the balance of the benefits, harms, and costs is too close to justify a general recommendation. D GDT recommends against routinely providing the intervention to eligible patients GDT found at least fair evidence that the intervention is ineffective, or that harms or costs outweigh benefits I GDT concludes that the evidence is insufficient to recommend for or against routinely providing the intervention. At the discretion of the GDT, the recommendation may use the language "option" but must list all the equivalent options.
Evidence that the intervention is effective is lacking, of poor quality, or conflicting, and the balance of benefits, harms, and costs cannot be determined The original postmenopausal bleeding guidelines and subsequent revisions were developed using the identified evidence and, where deemed necessary by the participants, a consensus process with which to classify, interpret, and develop components of the guideline not evaluated adequately by the literature. Evidence was classified using a modification of the system adopted by the US Preventive Services Task Force of the Agency for Healthcare Research and Quality (Table 2) , adding a subgroup for Class 1 evidence to allow for meta-analysis of randomized controlled trials, such as a Cochrane review. An additional modification was to include the creation of a Class 7 grouping that isolated expert opinion, including that from guidelines or other consensus documents from national or international organizations or from the collective opinion of the AUBWG members. The recommendations were created and classified according to the strength of the evidence and classified according to the system used by KPSC Guideline Development teams (Table 3 ). The term good evidence used in the text or tables indicates that either Grade A or Grade B evidence was available to support the recommendations (Table 4 ). The process was designed to be a continuous one, allowing for ongoing modifications and revisions as new, higher quality or otherwise clarifying evidence becomes available.
The original consensus document was created, approved by the members of the AUBWG in October 2004, and then submitted to the SCPMG Regional Chiefs for review, comment, and approval. Specifically, the Chiefs selected the 5-mm endometrial echo complex (EEC) thickness as the evidence-based threshold above which endometrial sampling is recommended. Following the 2012 review of the available evidence, the recommended threshold was changed to 4 mm. Minor modifications of the guideline were made following presentation to the SCPMG Regional Chiefs of Obstetrics and Gynecology. The revised guidelines were unanimously approved by the Regional Chiefs of Obstetrics and Gynecology on March 20, 2013.
Rationale

Introduction
Postmenopausal bleeding is a common patient complaint that is encountered by all physicians and other clinicians of gynecologic care. The clinician faces the possibility that there exists an underlying malignancy, while knowing that, in most instances, the bleeding comes from a benign source. In years past, the gold standard of clinical investigation was the institution-based dilation and curettage (D&C), but there now exists a number of office-based methods for the evaluation of women with this complaint. The postmenopausal use of gonadal steroids for the treatment of menopausal symptoms (HRT) is often associated with endometrial bleeding. Although the number of women using these agents decreased in the first decade of the 21st century, reevaluation of the literature and the release of new studies have collectively suggested that such therapy may provide benefit in at least selected instances. [1] [2] [3] As a result, clinicians will continue to be challenged by the issue of HRT-associated postmenopausal bleeding in the near future. It is known that tamoxifen and other SERMs may increase the chance of endometrial neoplasia developing. However, the proportion of postmenopausal women using such agents as adjuvant treatment of breast cancer is decreasing with the introduction of aromatase inhibitors 3 (Grade C). Nevertheless, there will continue to exist a number of women in their late reproductive years with unknown or uncertain ovarian endocrine status who experience abnormal bleeding in association with the use of these agents. Such women may have to be considered to have postmenopausal bleeding associated with the use of a SERM.
The clinician should appreciate that although the focus of investigation of postmenopausal bleeding is on the endometrium, bleeding in the postmenopausal woman may arise from a number of extraendometrial gynecologic and nongynecologic sites, such as the cervix, vagina, and urologic and gastrointestinal tracts. As a result, it is incumbent on the clinician to consider all these possibilities when evaluating a patient with postmenopausal bleeding or apparent unscheduled ("breakthrough") bleeding who is receiving HRT. Consequently, should the results of appropriately indicated and performed evaluation of the endometrium be normal, reevaluation for these potential causes is a prudent approach.
Definition of Postmenopausal Bleeding
The World Health Organization defines menopause as the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. 4 Because anovulatory "cycles" with episodes of multimonth amenorrhea frequently precede menopause, there is no consensus regarding the appropriate interval of Only selected women with bleeding associated with estrogen and progestin-containing hormone replacement therapy (HRT) require assessment of the endometrium. Uterine bleeding or spotting may be expected depending in part on the dose of HRT administered, in part on the schedule of progestin administration, and in part on the duration of therapy E B
12
It is not necessary to routinely evaluate the endometrium of women with uterine spotting or light uterine bleeding in the first six months of continuous estrogen and progestin HRT. Endometrial assessment of such women is recommended if spotting or bleeding persists beyond six months, although there is a very low incidence of endometrial hyperplasia or neoplasia E B
13
Women receiving doses of unopposed estrogen have a much higher incidence of endometrial hyperplasia and carcinoma, and require appropriate investigation of the endometrium E A 14 Women receiving estrogen and cyclical progestins can be expected to have indefinite progestin withdrawal bleeding and require no further investigation provided that the dose and duration of cyclic progestins is adequate E A
15
For women using cyclic progestins, bleeding outside the time of progestin withdrawal is considered abnormal and requires appropriate investigation
It is apparent that EEC thresholds used for spontaneous bleeding can be applied to patients with HRT-related bleeding, but with a higher incidence of false-positive findings
Women experiencing uterine bleeding while receiving tamoxifen (usually used as an adjuvant therapy for breast cancer) should be assessed primarily with endometrial sampling because, in such patients, TVUS is neither sensitive nor specific for neoplasia Table 2 ; strength of evidence is not applicable (N/A) to consensus-based recommendations.
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Investigation of Women with Postmenopausal Uterine Bleeding: Clinical Practice Recommendations amenorrhea preceding an episode of bleeding that would allow for the definition of postmenopausal uterine bleeding. For the purposes of this guideline, an episode of bleeding 12 months after the last menstrual period will be deemed to constitute postmenopausal bleeding. However, and especially in the perimenopausal years, the definition of "last period" may be difficult to ascertain, so liberal use of assays for estradiol and follicle stimulating hormone will help to determine when bleeding is occurring absent measurable ovarian function. For women receiving HRT, bleeding is common, and its frequency and timing depends in part on the scheduling of the gonadal steroids used, particularly the progestational agent 5 (Class 5). Breakthrough bleeding is unscheduled uterine bleeding that occurs in women receiving either estrogen alone or both estrogen and progestin therapy, which does not include the withdrawal bleeding that occurs following the cyclic withdrawal of progestin treatment. About 50% of women using continuous estrogen-progestin combined replacement regimens experience breakthrough bleeding, with most cases resolving 6 months after initiation of therapy 6 (Class 4). The following definitions of abnormal bleeding during HRT are suggested b : • For women using cyclically administered progestins in combination with a cyclical or continuous estrogen: 1) occurs at an unscheduled time or 2) occurs at the anticipated time after progestin withdrawal but is heavy or prolonged.
• For women using continuous combined estrogen and progestin-containing regimens: 1) commences six months or more after initiation or 2) commences after amenorrhea has been established.
Risk of Endometrial Cancer
In the US, endometrial cancer is the most commonly diagnosed reproductive tract malignancy and is the fourth most common cancer among women, trailing only cancers of the breast, lung, and colorectal origin 7 (Class 5). Although endometrial cancer accounts for 6% of all female cancers, a number of intrinsic clinical features, including a propensity for early diagnosis (because of investigation of abnormal or postmenopausal bleeding) and the prompt use of effective therapy, it causes only about 3% of all cancerrelated deaths.
There are 2 distinct types of endometrial cancer; most are Type 1, which develops secondary to unopposed estrogen-induced endometrial hyperplasia with an endometrioid appearance on histopathologic evaluation. Type 2 lesions comprise the minority, are of serous or clear cell origin, are not related to estrogen exposure, and are associated with a relatively poor prognosis. Older literature would suggest that Type 2 endometrial cancers comprise between 16% and 35% of endometrial cancer cases 8, 9 (Class 5), but more recent data from the US reveal that approximately 90% are Type 1 and about 10% are Type 2 lesions 10 (Class 5). For women with postmenopausal bleeding who do not use HRT, the incidence of endometrial cancer ranges from 4.9% to 11.5% [11] [12] [13] [14] (Class 5). There appears to be a greater risk of endometrial cancer in women who present with postmenopausal bleeding 10 or more years following menopause. One relatively large study found that postmenopausal bleeding over the age of 60 years was associated with a 13% risk of endometrial cancer 11 (Class 5) . Another large cohort study of slightly more than 3000 women with postmenopausal bleeding identified a peak in the age group from 60 through 64 years, of whom 7% were found to have endometrial cancer; the risk was lower for those in the younger and older age groups 14 (Class 5). There are no reliable data regarding the incidence of endometrial carcinoma in women using estrogen and progestincontaining HRT regimens. However, the estimated proportions range from 0.02% to 0.05% per annum [15] [16] [17] (Class 5). For women receiving tamoxifen, the risk of endometrial cancer is likely above 10% depending in part on the dose and in part on the duration of therapy [18] [19] [20] [21] (Class 4).
Suggested Contents for Report of Endometrial Echo Complex (EEC) Evaluation
Normally Configured Uterus, EEC well seen The uterus measures __ __ .__ cm in length; the corpus__ __ . __cm in width, and __ __ . __ cm in anterior-posterior thickness. The EEC is seen in its entirety in both the sagittal and transverse planes, is consistent in thickness and echogenicity, and measures __ __ . __ mm throughout. Comment:________________________________________________
Uterus with EEC well seen, endometrial cavity containing sonolucent fluid
The uterus measures __ __ .__ cm in length; the corpus__ __ . __cm in width, and __ __ . __ cm in anterior-posterior thickness. The EEC is seen in its entirety in both the sagittal and transverse planes, and contains sonolucent fluid. The endometrium on both sides of this fluid is consistent in thickness. The two-layer endometrial thickness calculated by subtracting the thickness of the fluid from the total endometrial echo complex thickness is __ __ . __ mm. Comment:________________________________________________ 
Generic
Relationship to Age
The national registries of nations with government-supported health care programs provide information regarding demographic variables associated with the risk of endometrial carcinoma. The incidence of endometrial cancer is very low below the age of 50 years, and especially before 40 years. The Scottish national data suggest that the incidence of endometrial carcinoma is about 6 to 8/100,000 women each year after the age of 50 years 22 (Class 4). However, these data do not describe the risk of endometrial cancer in women presenting with postmenopausal bleeding. Swedish data demonstrate that the incidence of postmenopausal bleeding declines with succeeding years after menopause and that the incidence of endometrial carcinoma increases as the age of the patient with postmenopausal bleeding increases 12 (Class 4).
Hormone Replacement Therapy
The relative risk of development of endometrial cancer for a woman receiving unopposed estrogen preparations in historically typical doses is about 5 times that for nonusers 17 (Class 4). This increased risk is almost, if not totally, eliminated if appropriate cyclic or continuous progestins are added to the regimen 17 (Class 4), 23 (Class 1a), 24 (Class 1b). However, a number of features may affect these risks, including the dose of the estrogen, and the dose, route, and regimen used to administer the progestin.
Most of the high-quality evidence relating to estrogen and progestin type and dosing and the risks of endometrial neoplasia has been obtained from randomized trials using endometrial hyperplasia as a surrogate outcome, studies that are well summarized in The Cochrane Database of Systematic Reviews 25 (Class 1a). Unopposed estrogen, compared with placebo, is associated with an odds ratio (OR) for the shortterm (18- 29 (Class 4). These increases were not seen with continuous progestin regimens, including the use of the intrauterine progestin releasing system. There is relatively recent evidence that ultralow doses of unopposed estrogen may not increase the incidence of endometrial carcinoma, but these preparations are not yet in widespread use 30, 31 (Class 3). Furthermore, there is good evidence that even doses as low as 0.3 mg/day of unopposed equine estrogens are associated with an increased risk of endometrial hyperplasia 25 (Class 1a).
The addition of a progestin to an estrogen-based HRT regimen is frequently associated with bleeding-generally predictable with cyclic progestin therapy and unpredictable for women receiving continuous treatment with progestin preparations 32, 33 (Class 4). As a result, the proportion of women having underlying endometrial carcinoma can be expected to be much lower in women using combined HRT regimens than it is for those using estrogen alone or, depending on the formulation and schedule, for those receiving no HRT at all 34 (Class 4).
Endometrial Cancer and Tamoxifen
Tamoxifen is a nonsteroidal compound in the family of SERM 35 that possesses weak estrogen activity similar to clomiphene citrate. Each of these agents is used to flood estrogen receptors with relatively inactive hormones, an approach designed to diminish estrogen-related cellular function. For those women using tamoxifen as adjuvant therapy for breast cancer, there is a substantial reduction in the rate of recurrence of breast cancer, but there is also a 3 to 6 times increase in the incidence of endometrial carcinoma [18] [19] [20] [21] (Class 4). This risk is proportional both to the dose of the drug and the duration of therapy, with those women treated for 5 or more years experiencing a fourfold risk 36, 37 (Class 4). Some evidence exists that, for women in whom endometrial carcinoma develops following prolonged tamoxifen use, both the grade and stage of the tumor may be higher, thereby potentially compromising survival 38 (Class 4). Formerly there was controversy regarding the most appropriate approach to monitoring the endometrium in women using tamoxifen, with some investigators suggesting that routine endometrial sampling be performed on an annual basis. However, current evidence suggests that such an approach consumes resources without improving survival rates 39, 40 (Class 3). Consequently, and at least for the present, only women receiving tamoxifen who experience uterine bleeding should be investigated.
Although not strictly within the scope of this guideline, the management of nonbleeding women with a thickened endometrium (thick EEC) who are receiving tamoxifen is a potential issue. Evidence from studies evaluating this issue fails to support the notion of routine sonographic screening 41 (Class 5), at least in part because there is no evidence for a clinically useful EEC threshold in tamoxifen-treated patients 40 (Class 3). These findings, often cystic in nature, represent a unique, reversible, tamoxifen-induced change 42 (Class 5).
Relationship to Hereditary Nonpolyposis Colonic Cancer
A number of other factors are associated with an increased risk of endometrial cancer. Hereditary nonpolyposis colorectal cancer is a relatively common, autosomal dominant syndrome originally described by Henry Lynch, and it is still known in some quarters by the name Lynch syndrome, particularly if there is a known DNA mismatch pair. Endometrial cancer is the most common extracolonic cancer found in women with this syndrome. The estimated lifetime risk of endometrial cancer in women with Lynch syndrome is 42% to 60% 43, 44 (Class 5) and, unlike spontaneous endometrial cancer, these malignancies often present in the premenopausal years 45 (Class 4).
Other Risk Factors for Endometrial Cancer
The evidence linking other risk factors to the development of endometrial cancer is relatively weak. These include obesity, hypertension, and a history of either endogenous or exogenous hyperestrogenism 46 (Class 5).
Clinical Investigation of Women with Postmenopausal Vaginal Bleeding Physical Examination
Pelvic examination should be performed searching for visual evidence of lesions or bleeding from gynecologic (eg, vulva, vagina, exocervix) and nongynecologic (eg, perineum, periurethral, perianal) sources.
Evaluation of the Endometrium
Histologic Assessment
Sampling of the endometrium can be accomplished by devices designed for office use, by D&C, or under hysteroscopic direction. Office-based sampling is usually performed with disposable catheters that allow for the application of suction to obtain a specimen. Any method of sampling the endometrial cavity misses a proportion of endometrial cancers 24 (Class 1b), 47, 48 (Class 3), 49 (Class 5).
Dilation and Curettage
D&C should no longer be the first method of sampling the endometrium in most cases. (Class 3) . Collectively, these data would suggest that women with "nondiagnostic" endometrial biopsy specimens should have additional uterine evaluations with TVUS, contrast sonography, hysteroscopy, or a combination of any of these procedures.
Comparison of Office-Based Sampling Systems
There are a number of issues to consider when comparing office-based endometrial sampling catheters, including ease of use, procedure-associated pain, frequency of obtaining adequate samples, number of passes required to obtain those samples, and cost. The Pipelle device has been shown, in the context of a randomized trial, to be superior to the Vabra aspirator (Berkeley Medevices Inc; Richmond, CA; USA), with adequate tissue being found in 73.3% vs 52.4% of cases 54 (Class 1b). The Pipelle device has also been compared with the Explora catheter (CooperSurgical Inc; Trumbull, CT; USA) in a randomized 
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trial; results showed the Explora to be slightly superior regarding proportion of adequate samples (97% vs 91%) 55 (Class 1b). However, in randomized trials from Scotland, the Tao Brush (Cook Medical; Bloomington, IN; USA) was found to be superior to the Pipelle catheter in obtaining a satisfactory endometrial sample (72% to 43%) 56, 57 (Class 1b). Endometrial cytology with liquid-based techniques has also been described to have a high sensitivity for carcinoma, but it has not been compared with blind sampling 58 (Class 3). Clearly, more comparative trials are necessary to determine the optimum combination of effectiveness, cost, and procedure-related pain.
Blind Endometrial Sampling
Blind methods of endometrial sampling frequently fail to identify focal pathology of the endometrium. Although blind sampling, either by endometrial biopsy or D&C, is a satisfactory first-line technique for the detection of endometrial neoplasia that affects the entire endometrial surface, it is inadequate at detecting localized lesions such as endometrial polyps, which may be malignant [59] [60] [61] (Class 3) . Indeed, a well-designed prospective study demonstrated that even D&C performed in the operating room missed endometrial polyps about half the time 60 (Class 3). This information would suggest that in the presence of symptoms or evidence of a focal lesion, or, following blind sampling, if symptoms of postmenopausal bleeding persist, imaging of the endometrial cavity should be performed with one or a combination of the following: TVUS, contrast sonography, or hysteroscopy.
Transvaginal Ultrasonography
Compared with premenopausal women, the measured thickness of the endometrium (by convention a double layer in the midsagittal view; Figure 1 ) should be thinner in postmenopausal women not receiving HRT (Figure 2 ). This double-thickness layer is called the EEC. If there is uniformly sonolucent fluid-generally a nonconcerning finding-the thickness of the fluid echo is subtracted from the measurement from baseline to baseline to obtain the EEC (Figure 3 ). The morphologic features should be uniform and, if there are irregularities, or if the EEC cannot be adequately evaluated (Figure 4 ), other investigations are warranted, such as contrast sonography, hysteroscopy, and/ or endometrial sampling. At this time, available evidence suggests that there are no advantages offered by the use of 3-dimensional ultrasonography, as compared with standard 2-dimensional ultrasonography 62 (Class 3). In general, thicker EECs are associated with a greater likelihood of endometrial or intracavitary pathology, including endometrial polyps, hyperplasia, and cancer 63 (Class 3). On the other hand, the reliability of TVUS allows the clinician to identify a group of women with postmenopausal bleeding who have a thin endometrium and thus a very low likelihood of hyperplasia or neoplasia. Unless there is a recurrence of bleeding, this group of women with postmenopausal bleeding and a thin EEC generally require no more investigation [64] [65] [66] (Class 2). There is some evidence that TVUS may be less sensitive for the detection of Type 2 endometrial carcinomas regardless of the EEC threshold. A cohort study demonstrated that 17% of patients with postmenopausal bleeding and Type 2 endometrial cancer had an EEC of less than 4 mm 67 (Class 5). A number of EEC thickness thresholds have been published to guide clinicians in discriminating between women who require endometrial sampling and those who do not, at least for the first episode of postmenopausal bleeding ( Table 5 ). The thinner the threshold, the fewer cases of hyperplasia and cancer missed, but with higher sensitivity, specificity is reduced and more endometrial sampling must be performed. Furthermore, the use of HRT can have a variable impact on the measurements depending on the use of a progestin. Continuous estrogen-progestin regimens tend to cause a hypotrophic and sonographically thin endometrium, whereas the EEC in women receiving regimens of continuous estrogen and cyclically administered progestins will vary according to the date of the TVUS and the cycle date in the HRT regimen. Available evidence suggests that women with postmenopausal bleeding and a thickened endometrium are less likely to have endometrial pathology when they are receiving HRT than when they are not 65, 68 (Class 2). Presumably, the endometrial thickness in women receiving estrogen and cyclic progestin therapy would be lowest shortly after the cessation of the progestins, a time that might be best suited for measurement of EEC thickness in women who experience unscheduled bleeding.
Normal Thickness of Endometrial Echo Complex
Meta-analytic research using "summary data" has been performed using high-quality studies evaluating the utility of TVUS-obtained EEC thickness for the assessment of women with postmenopausal bleeding. The authors of the largest meta-analysis to date, with just more Thickness of fluid (B) is subtracted from distance between base of opposing layers of endometrium (A). These should be in the same plane; they are separated slightly here for demonstration purposes.
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than 9000 patients, demonstrated that an EEC of 3 mm or less would provide a posttest probability of 0.4% for endometrial cancer; a 4-mm threshold, 1.2%; and a 5-mm threshold, 2.3% 66 (Class 2). In this study, the best quality evidence was that for the 5-mm threshold. 66 The authors of a second large meta-analysis of nearly 6000 women reported that an EEC of 5 mm or less was associated with a 4% chance of endometrial cancer. This sensitivity did not vary in women using HRT 65 (Class 2). Meta-analysis using the original datasets is thought to provide more accurate conclusions than using the summary data provided in the published manuscript because of a number of factors, including publication bias, method of analysis, and length of follow-up 69, 70 (technical descriptions). One such analysis employed this technique but, rather than using fixed cutoffs for EEC, used multiples of the mean for each different study and determined that if the median EEC thickness was used, the sensitivity would be approximately 96% and specificity would be 50%. However, such an approach is difficult to evaluate and implement because it does not provide guidance about EEC thickness overall 71 (Class 2). Consequently, Timmermans et al 72 (Class 2) performed a reanalysis of the data using original datasets, rather than summary data, and were able to evaluate 2896 cases from 13 authors (259 with endometrial carcinoma), only 2 of which were from the original 90-author group reported in the publication by Smith-Bindman et al 65 (Class 2). The conclusions from this analysis suggested that a threshold of 5 mm for the EEC would have sensitivity for endometrial cancer of only 90%; 4 mm, a sensitivity of 95%; and 3 mm, a sensitivity of 98%-thresholds that are different from those found in the previously published meta-analyses. No original dataset analyses were reported considering the impact on EEC thickness.
Before this individual dataset-based meta-analysis, the Scottish Intercollegiate Guidelines Network chose the 3-mm thickness for the following 3 groups of postmenopausal women with postmenopausal bleeding 73 (evidence-based guideline): 1) never used HRT, 2) discontinued HRT a year or more earlier, and 3) using continuous combined HRT. The Scottish Intercollegiate Guidelines Network also set a different threshold for women receiving estrogen and cyclic progestin therapy and estimated that, in the context of unscheduled bleeding, the risk of endometrial cancer for such women was 0.2% if the EEC was 5 mm or less.
The American College of Obstetricians and Gynecologists has published a practice bulletin that recommended an EEC threshold of 4 mm, above which other techniques of endometrial assessment should be employed. 74 The issue of HRT and its impact on EEC thresholds is not dealt with in that guideline (evidencebased guideline).
Endometrial Fluid Found with Transvaginal Ultrasonography
As described previously in this section, fluid may be identified between the sonographically determined endometrial layers in both symptomatic and asymptomatic women 75 (Class 5; Figure 3 ). Such a finding had previously been thought to be a predictor of malignancy, but more recent evidence challenges such a conclusion. The issue may be particularly relevant in the presence of cervical stenosis, when access to the endometrial cavity for endometrial sampling or hysteroscopy may be limited. Although there remains a relative paucity of studies evaluating this finding, existing con- 
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Investigation of Women with Postmenopausal Uterine Bleeding: Clinical Practice Recommendations temporary studies are remarkably consistent demonstrating that if the fluid is sonolucent and if the EEC, which is the combined thickness of the 2 separated endometrial layers, is 3 mm or less (see Figure 3) , the finding is highly likely to be benign [76] [77] [78] (Class 3). On the other hand, if the EEC is greater than threshold (3.0-4.5 mm depending on the study) or if the fluid is echogenic 79 (Class 3), there is a risk of malignancy and immediate further investigation aimed at obtaining a tissue sample is warranted 80 (Class 3). Women with postmenopausal bleeding, intrauterine sonolucent fluid, and an EEC of 3 mm or less could still harbor a carcinoma in the cervical canal, so such a diagnosis should be considered 79 (Class 3).
Documentation
If TVUS or contrast sonography is used to evaluate women with postmenopausal bleeding or unscheduled bleeding who are receiving HRT, documentation ideally comprises both a midline sagittal image and a transverse fundal image documenting the thickest measurement of the EEC. A suitable note describing the findings should be included in the patient record 81 (Class 7). The addition to the record of selected images is desirable but not considered mandatory provided that the note describes the endometrial findings in sufficient detail.
Contrast Sonography
Transcervical instillation of saline (saline infusion sonography), or other sonographic contrast media such as gel, into the endometrial cavity allows for contrast-enhanced sonographic evaluation that is designed to improve diagnostic utility for lesions involving the endometrial cavity such as polyps or submucous leiomyomas 82 (Class 5). The procedure is performed in an office setting with a small-caliber catheter positioned in the endometrial cavity while imaging is performed with simultaneous TVUS. In addition to saline infusion sonography, such fluid contrast-enhanced ultrasonography of the endometrial cavity is known as sonohysterography and hysterosonography, although the latter two terms may create confusion with the contrast-enhanced radiographic evaluation of the endometrial cavity and fallopian tubes that is called a hysterosalpingogram. Consequently, for purposes of this document, the term contrast sonography or saline infusion sonography will be used.
The procedure appears to accurately evaluate the endometrial cavity and can be successfully performed in more than 85% of postmenopausal women in an office setting 83 (Class 2). Saline infusion sonography seems superior to TVUS in defining intrauterine lesions in women with postmenopausal bleeding and a measured EEC greater than 5 mm, particularly for the delineation of endometrial polyps, for which it seems as accurate as hysteroscopy 84 (Class 2). Another observer-blinded comparison demonstrated that saline infusion sonography was essentially equivalent to hysteroscopy and superior to TVUS for the diagnosis of endometrial cavity abnormalities in women with postmenopausal bleeding 85 (Class 3). There is no current evidence suggesting that saline infusion sonography enhances the diagnosis of malignancy. However, by virtue of its ability to identify postmenopausal women with endometrial polyps, saline infusion sonography may facilitate diagnosis, targeted removal, and resolution of symptoms, thereby reducing resource utilization and improving patient satisfaction with the overall process (Class 7).
Hysteroscopy with Curettage and Directed Biopsy
Hysteroscopy is an endoscopic technique that allows direct visualization of the endometrial cavity. It can be performed in an office setting with local or no anesthesia, with or without sedation, or in a procedure room or operating room. To accomplish the procedure, it is often necessary to first dilate the cervix adequately to accommodate the external diameter of the outer sheath of the hysteroscope assembly, which generally ranges from 4.0 to 5.5 mm. A number of small-caliber fiberoptic devices exist that are approximately the diameter of some biopsy catheters (3-4 mm). With such instrumentation, dilation of the cervix may not be necessary. One inherent advantage of hysteroscopy is that endoscopically guided removal of lesions may be performed immediately after diagnosis, during the same procedure. Provided that the lesions are relatively small, such excisions may even be performed in an office setting. Despite the seemingly obvious advantages of the technique, the data supporting the use of hysteroscopy for management of women with postmenopausal bleeding are relatively sparse and generally of relatively poor quality.
As described previously, hysteroscopy is superior to endometrial biopsy 60, 61, 67 (Class 3), D&C 60 (Class 3), and ultrasonography 84, 85 (Class 3) for the identification of structural lesions of the endometrium such as endometrial polyps. Hysteroscopy has good diagnostic accuracy for structural lesions, such as polyps and leiomyomas, whether or not performed in an office setting, and good patient acceptability in either setting 24, 86 (Class 1b). Indeed, in a study designed to determine the desires of women regarding a primary assessment tool for evaluation of postmenopausal bleeding, 95% preferred to undergo office hysterectomy rather than experience a 5% chance that a lesion could be missed 87 (Class 6). However, it should be noted that hysteroscopic visualization alone is relatively inaccurate in the diagnosis of atypical hyperplasia and carcinoma 84, 88, 89 (Class 3). Consequently, hysteroscopy should not be performed in women with postmenopausal bleeding who have not undergone antecedent or concurrent endometrial sampling by suction or sharp curettage.
In the past, there were concerns that the pressurized distending media used with hysteroscopy could result in retrograde dissemination of malignant cells into the peritoneal cavity sufficient to alter the prognosis of endometrial carcinoma 90, 91 (Class 5). However, although some investigators have shown a low incidence of peritoneal washings testing positive for endometrial cells 92 (Class 5), others have compared the incidence of positive peritoneal cytologic findings associated with hysteroscopy to that associated with D&C and have found the frequency to be similar-about 9% to 10% 93 (Class 1b), 94 (Class 4). Overall, there seems to be a slightly increased risk of positive peritoneal cytologic findings associated with the use of hysteroscopy (OR, 1.78; CI, 1.13-2.79) 95 (Class 1b). However, available high-quality evidence suggests that the prognosis associated with a hysteroscopic diagnosis of endometrial cancer is not different from that with other diagnostic methods 93 (Class 1b), 92, [96] [97] [98] (Class 3).
Sequencing of Investigations
The exact sequencing of investigations for women with postmenopausal bleeding will necessarily vary somewhat depending on the local resources and expertise, the judgment of the clinician, and patient preference. There is evidence that resource utilization is reduced if the practitioner is able to perform the TVUS examination in the office without adding additional charges as opposed to having the procedure performed by a radiologist 99 (Class 3), and this would be presumably true for contrast sonography as well. The same can be said for hysteroscopy, for which inoffice performance using local anesthesia is logically cheaper than any hospital or surgical center-based procedure.
Primary Assessment of Spontaneous Postmenopausal Bleeding
For women with spontaneous bleeding 12 or more months following the last menstrual period, the endometrium can be primarily assessed by either officebased endometrial biopsy ( Figure 5 ) or TVUS ( Figure 6 ). For those who undergo TVUS and have an EEC greater than 4 mm, localized thickening, or an indistinct or nonvisible EEC, endometrial sampling is a reasonable next step.
These approaches were compared by Weber et al 100 (Class 3) from the Cleveland Clinic in a cost-modeling exercise, with primary TVUS predicted as being slightly less expensive. However, in that study, the assumptions were based on a charge model and included performance of the TVUS in a Radiology Department. In another study, Medverd and Dubinsky 101 (Class 3) demonstrated that TVUS as a primary assessment modality utilized approximately 11% fewer resources than did an endometrial biopsy-originated evaluation paradigm. It is unclear whether charges or costs were considered in their analysis, but it is presumed that the imaging was performed in a Radiology Department and was interpreted by a radiologist. A cost modeling analysis from the UK, which assumed that a gynecologist performed all procedures, suggested that endometrial biopsy-and TVUS-initiated investigational paradigms were similar regarding their cost-effectiveness when 5 mm was used as the EEC threshold 102 (Class 3). How this analysis translates to US fee-for-service or prepaid models is unclear, and the impact of changing the EEC threshold to 4 mm was not evaluated.
Primary Assessment of Hormone Replacement Therapy-Related Postmenopausal Bleeding (Breakthrough Bleeding)
The increased risk of endometrial cancer for women with postmenopausal bleeding who are receiving unopposed estrogen requires assessment in all circumstances. For women with postmenopausal bleeding while receiving combined estrogen-progestin HRT regimens, the approach is less clear, as it is apparent that such women are at significantly reduced risk of endometrial carcinoma compared with women not receiving HRT 103 (Class 5). Furthermore, women using estrogen and cyclic progestin therapy and who have cyclic bleeding near to or following the end of the progestogenic component of the regimen require no investigation. In addition, those women who use estrogen and continuous progestin regimens will frequently experience breakthrough bleeding in the first 6 months of therapy and generally require no investigation. However, women receiving cyclic progestin regimens who have unscheduled bleeding, or for those receiving continuous progestin therapy who have breakthrough bleeding beyond 6 months and especially following a period of amenorrhea, the endometrium should be assessed. Available evidence suggests that either endometrial biopsy or TVUS can be used in a fashion similar to that recommended for spontaneous bleeding using a similar EEC threshold for endometrial sampling 65 (Class 2), 68 (Class 5). Although it is possible that a higher EEC threshold might apply to women receiving sequential HRT, the committee could Entire EEC should be seen, allowing demonstration of a consistent 2-layer thickness in both the sagittal and transverse planes that is less than or equal to 4 mm. If there is clear (sonolucent) fluid, the bilaminar endometrial thickness should be less than or equal to 3 mm. AUB = abnormal uterine bleeding; HRT = hormone replacement therapy; TVUS = transvaginal ultrasonography; ± = with or without. A satisfactory EB comprises perceptible passage of the sampling device through the cervical canal into the endometrial cavity and appropriate functioning of the aspiration mechanism. Adequacy of the specimen for histologic interpretation is determined by the pathologist. AUB = abnormal uterine bleeding; EEC = endometrial echo complex; HRT = hormone replacement therapy; TVUS = transvaginal ultrasonography; ± = with or without.
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Investigation of Women with Postmenopausal Uterine Bleeding: Clinical Practice Recommendations not find convincing evidence to support such a notion. Consequently, clinicians are encouraged to perform TVUS for EEC measurement in the early phase of the "cycle" shortly after the completion of the progestin component.
Unless appropriately trained in either endometrial sampling techniques or TVUS, the primary care provider should refer any patient whose postmenopausal bleeding fits within the criteria requiring endometrial assessment. The gynecologist should determine which patients, if any, require TVUS assessment, including those who should be referred to a radiologist or other individual with specialist training in ultrasound of the uterus.
Investigation of Postmenopausal Bleeding in Women Receiving Hormone Replacement Therapy
Evaluation of women with postmenopausal bleeding while using HRT is affected by a number of factors, including the type of regimen, the dose of estrogen, and, if used, the scheduling of progestin administration (cyclic or continuous). These and other factors have an effect on the nature and timing of anticipated and unscheduled bleeding and may have a role in the timing and interpretation of ultrasound findings.
Causes of Abnormal Uterine Bleeding
Causes of abnormal bleeding in women using HRT include the following:
• Poor compliance 
Important Points in the Patient History
The clinician should determine if the bleeding pattern is within acceptable limits (see earlier section, Hormone Replacement Therapy). In addition, the provider should ascertain if there are any other factors or symptoms that may place the patient at increased risk of endometrial cancer. Pertinent questions to ask include the following:
• When does the bleeding occur with respect to progestin administration? Women receiving cyclical progestin therapy should have bleeding near the end of or shortly after discontinuation of the progestin component of the regimen. Transvaginal ultrasonography is not sufficient for the evaluation of women experiencing bleeding while receiving tamoxifen. Endometrial sampling is necessary. AUB = abnormal uterine bleeding; ± = with or without.
• The intentional or inadvertent use of other gonadal steroids (estrogens with or without progestins) may explain unexpected bleeding.
Discontinuation of Hormone Replacement Therapy before Clinical Investigation
There is no convincing reason to discontinue HRT before clinical investigation. If the primary physician is able to complete the required investigative steps, this issue is moot. However, if the physician will be referring the patient for clinical assessment by a gynecologist, there may be a time period between the referral and the actual consultation appointment. In such instances, women may continue their regimen (Class 7).
Recurrent Spontaneous or Breakthrough Bleeding
Spontaneous or HRT-related, recurrent postmenopausal bleeding can oc-
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Investigation of Women with Postmenopausal Uterine Bleeding: Clinical Practice Recommendations cur. In a prospective study of women with postmenopausal bleeding who were not receiving HRT and whose EEC measured 4 mm or less, the incidence of recurrent bleeding was 10% at a mean of 49 weeks following the original TVUS 104 (Class 5). Of these 25 patients, 8% (n = 2) had endometrial carcinoma and 4% (n = 1) had a malignant melanoma. In another retrospective study of 1536 women with postmenopausal bleeding evaluated over a period of almost 5 years with both TVUS and endometrial biopsy, the prevalence of endometrial cancer was 3% with primary assessment. 105 On the other hand, the prevalence was 4% in the 126 patients with normal results of the initial evaluation who presented with persistent postmenopausal bleeding 105 (Class 5). There is no current evidence supporting any specific recommendations for reinvestigation in the face of a normal TVUS or satisfactory and normal endometrial biopsy specimen. However, considering the false-negative rates associated with either approach, the indications for reassessment should be rather liberal considering one or a combination of repeat TVUS, repeat endometrial biopsy, and contrast sonography or hysteroscopy 64, 106 (Class 5), 49 (Class 6), 107 (Class 7). Determination of the specific order and combinations of these investigations will depend on the clinical judgment of, and resources available to, the clinician.
Tamoxifen-Related Bleeding
As previously described, patients receiving tamoxifen who are postmenopausal experience an increased risk of endometrial neoplasia that is greatest after four years of exposure. Whereas there is no evidence to support the use of routine biopsy of such patients, any who present with bleeding while receiving tamoxifen should undergo office-based endometrial sampling if possible (Figure 7) . If not feasible, such patients should undergo hysteroscopy and curettage.
The tamoxifen-induced impact on the endometrium frequently, if not usually, creates a thickened EEC, often with diffuse subendometrial cystic change that is in no way indicative of endometrial hyperplasia or malignancy [108] [109] [110] [111] [112] [113] (Classes 2-4). As a result, TVUS for evaluation of EEC thickness is not useful in the evaluation of tamoxifenrelated postmenopausal bleeding.
Many patients with tamoxifen-related bleeding have endometrial polyps 114, 115 (Class 1b). Consequently, if bleeding persists, evaluation of the endometrial cavity is indicated, generally with hysteroscopy, with hysteroscopically guided excision of any identified polyps and curettage for reassessment of the endometrium. Contrast sonography may also be useful in this regard; however, there is evidence that saline infusion sonography is inferior to hysteroscopy in detecting focal lesions in these patients 116 
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